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Abstract The bHLH transcription factor, OLIG2, is
universally expressed in adult human gliomas and, as a
major factor in the development of oligodendrocytes, is
expressed at the highest levels in low-grade oligoden-
droglial tumors. In addition, it is functionally required for
the formation of high-grade astrocytomas in a genetically
relevant murine model. The pediatric gliomas have geno-
mic profiles that are different from the corresponding adult
tumors and accordingly, the expression of OLIG2 in non-
oligodendroglial pediatric gliomas is not well documented
within specific tumor types. In the current study, the pattern
of OLIG2 expression in a spectrum of 90 non-oligoden-
droglial pediatric gliomas varied from very low levels in
the ependymomas (cellular and tanycytic) to high levels in
pilocytic astrocytoma, and in the diffuse-type astrocytic
tumors (WHO grades II–IV). With dual-labeling, glio-
blastoma had the highest percentage of OLIG2 expressing
cells that were also Ki-67 positive (mean = 16.3%)
whereas pilocytic astrocytoma WHO grade I and astrocy-
toma WHO grade II had the lowest (0.9 and 1%,
respectively); most of the Ki-67 positive cells in the dif-
fuse-type astrocytomas (WHO grade II–III) were also
OLIG2 positive (92–94%). In contrast to the various types
of pediatric astrocytic tumors, all ependymomas WHO
grade II, regardless of site of origin, showed at most
minimal OLIG2 expression, suggesting that OLIG2 func-
tion in pediatric gliomas is cell lineage dependent.
Keywords Pediatric glioma  Pilocytic astrocytoma 
Pediatric astrocytoma  Pediatric ependymoma  OLIG2
Abbreviations
bHLH Basic helix loop helix
CBTRUS Central Brain Tumor Registry of the United
States
F-T-P Lobes Frontal-temporal-parietal lobes of cerebral
cortex
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
IDH1 Isocitrate dehydrogenase 1
OLIG2 Oligodendrocyte lineages transcription
factor 2
PDGF Platelet derived growth factor
PTEN Phosphatase and tensin homologue
SEGA Subependymal giant cell astrocytoma
WHO World Health Organization
Introduction
Neuroepithelial tumors containing various glial lineages
are the most common primary central nervous system
(CNS) tumor in all age groups. Pediatric CNS tumors
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constitute a large group of solid neoplasms that arise within
the first two decades and are the second most common
malignancy in children, second only to leukemia [1]. In
pediatric patients, gliomas account for 45–56% of all CNS
tumors and 74–81% of all malignant CNS tumors [2].
Within this group, the non-oligodendroglial gliomas are a
leading cause of solid tumor-related morbidity and mor-
tality in children. The development of effective therapies
for these tumors has been limited, in part due to a limited
understanding of the genetic alterations responsible for
their development and progression.
Several lines of evidence suggest that the activity of
OLIG2 provides a mechanistic link between growth of
malignant glioma progenitors and neural stem cells. First, a
subpopulation of type B and type C progenitor cells in the
adult rodent brain express OLIG2 [3–5]. Second, exposure
to glioma relevant mitogens such as EGF or PDGF [6]
stimulates proliferation of OLIG2? rapidly dividing ‘‘type
C’’ transit amplifying cells and glioma-like growths. All
adult malignant gliomas, irrespective of grade, express
OLIG2 in at least a fraction of the malignant cell population
[7, 8]. Third, OLIG2 function is required for tumorigenesis
in a genetically relevant mouse model of adult human gli-
omas that commonly show activation of EGF signaling and
mutation of the tumor suppressor INK4A/ARF [9].
The pediatric gliomas share histopathologic similarities
with their corresponding adult counterparts, even though
they do not have the same signature genetic mutations, such
as genomic alterations in the EGFR, PTEN, and TP53
[10–15]. Although TP53 mutations are present in several
groups of pediatric gliomas, the frequent genetic alterations
detected in adult WHO grade II-IV astrocytomas, including
IDH1 mutations, are identified at significantly lower fre-
quencies in pediatric gliomas [1, 16–19]. Recently, several
studies have shown that a majority of pilocytic astrocytomas
in both pediatric and adult patients harbor 7q34 duplications,
which result in gene fusions between KIAA1549 and
BRAF with the concomitant expression of KIAA1549:B-
RAF fusion transcripts [20, 21]. In addition, a number of
pediatric infiltrating gliomas (WHO grades II-IV) also
appear to harbor an activating BRAFV600E mutation that
may also occur with homozygous deletions in the CDKN2A
gene [22]. The question of the prevalence of OLIG2 expres-
sion in the non-oligodendroglial pediatric gliomas is rele-
vant in view of the genomic distinctions within pediatric
astrocytic tumors and distinct biological features of these
tumors in contrast to their adult counterparts.
Materials and methods
Patient material selection
Pediatric brain tumor cases from 1990 to 2008 were
retrieved from the UCSF Pathology archives. Neurosurgi-
cal patients below 20 years of age with a primary brain
tumor of glial origin were included in this study, but cases
of recurrent tumors were grouped separately from primary,
newly diagnosed tumors undergoing first resection. A total
of 90 pediatric cases were retrieved from the archives that
met these criteria (see Tables 1, 2; Fig. 1 for further
information). Many of these cases had been originally
Table 1 OLIG2 expression in primary CNS tumors
Diagnosis Average age (years) M/F Mean OLIG2 score SD
Glioblastoma, WHO grade IV 8.7 2M/4F 3 0
Anaplastic astrocytoma, WHO III 7.6 8M/5F 2.2 0.9
Recurrent anaplastic astrocytoma, WHO III 17 2M/0F 3 0
Astrocytoma, WHO II 10.6 9M/4F 2.6 0.8
Recurrent astrocytoma, WHO II 11.8 2M/2F 1.4 1.1
Pilocytic astrocytoma, WHO I 6.9 13M/19F 3 0.18
Recurrent pilocytic astrocytoma, WHO I 10.5 2M/0F 2.5 0.7
Ependymoma, WHO II 10.1 4M/4F 0 0
Recurrent ependymoma, WHO II 7.5 1M/1F 0.4 0.5
Anaplastic ependymoma, WHO III 7.8 3M/1F 0.25 0.5
Myxopapillary ependymoma 15 1M/1F 1.5 2.1
SEGA 6 1M/1F 0 0
Pediatric brain tumors were scored for OLIG2 expression by immunohistochemistry. Ependymomas (including one tanycytic variant) showed no
OLIG2 staining, whereas one myxopapillary ependymomas showed strong OLIG2 expression. WHO II and pilocytic astrocytomas showed
decreased OLIG2 staining after treatment, but this value is not statistically significant by ANOVA. Recurrent neoplasms, i.e., a treated neoplasm
y Years, M/F number male patients/number female patients, ST error standard error of the mean, WHO world health organization, roman
numerals WHO grade
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diagnosed using non-WHO grading criteria, and therefore a
thorough review of all cases was carried out jointly by the
authors (JO and SV) to assign accurate 2007 WHO grade
for each case. Both authors agreed with the final diagnosis
and WHO grade. For comparison to the pediatric
ependyomomas, 10 cases of adult ependymoma were
analyzed: 3 myxopapillary ependymoma, WHO grade I
(average age = 32 years, two female, one male); 6 epen-
dymoma, WHO grade II (average age = 33.7 years, three
male, three female); 1 anaplastic ependymoma, WHO
grade III (54 year old male). Hematoxylin and Eosin
(H&E) stained sections were reviewed by the authors (SRV
and JJO) for diagnostic confirmation and to select appro-
priate tissue blocks for subsequent OLIG2 immunoperox-
idase staining. Specifically, one H&E stained section and
one OLIG2 stained section was evaluated. During review
of OLIG2 stained sections, access to the original patho-
logical diagnosis was permitted. Full concordance in
diagnosis and OLIG2 expression was established for all
cases studied. Selection of histologic sections for immun-
operoxidase stains required the following criteria: (1) the
section had to be representative of the final diagnosis, (2)
only tissue that was formalin fixed while fresh and paraffin
embedded was used (i.e., remnants from previously frozen
tissue were excluded from the study), and (3) sufficient
material had to be present for evaluation (greater than or
equal to 0.01 cm2 of tissue per slide and multiple blocks if
possible). The definition of brainstem included midbrain,
pons, and medulla. The definition of deep gray matter used
in this study includes tumors arising in hypothalamus,
thalamus, basal ganglia, and striatum.
Immunohistochemistry techniques
All tissue was routinely fixed in either phosphate buffered
4% formalin or Zn-4% Formalin, dehydrated by graded
ethanol washes and embedded in wax (Paraplast Plus,
McCormick Scientific) using routine techniques. All sec-
tions were cut at 5 lm thickness and mounted upon Su-
perfrost/Plus slides (Fisher Scientific). Antibodies were
obtained from the following sources and used at the fol-
lowing dilutions and incubation times/temperatures: (1)
OLIG2 rabbit polyclonal antibody DF308 (From lab
stocks, [23]): 1:50, 32 min at 37; (2) Anti Ki-67 rabbit
polyclonal (Anti-Ki-67(30-9), Ventana Medical Systems,
Tucson, AZ) 2 lg/ml, 32 min at 37. Epitope retrieval for
Table 2 CNS tumors showing
statistically significant OLIG2
expression
ANOVA/Tukey HSD test were
performed to test which tumor
comparisons showed a
statistically significant
difference in OLIG2 expression.
Only tumor comparisons with
statistical significance are listed
P adjusted probability
calculated by Tukey HSD test
Tumor 1 Tumor 2 P value
Anaplastic ependymoma, WHO III Anaplastic astrocytoma, WHO III \1 9 10-5
Ependymoma, WHO II Anaplastic astrocytoma, WHO III \1 9 10-5
Pilocytic astrocytoma, WHO I Anaplastic astrocytoma, WHO III 0.017
Recurrent ependymoma, WHO II Anaplastic astrocytoma, WHO III 0.0058
SEGA, WHO I Anaplastic astrocytoma, WHO III 3 9 10-4
Astrocytoma, WHO II Anaplastic ependymoma, WHO III \1 9 10-5
Glioblastoma, WHO IV Anaplastic ependymoma, WHO III \1 9 10-5
Pilocytic astrocytoma, WHO I Anaplastic ependymoma, WHO III \1 9 10-5
Recurrent anaplastic astrocytoma, WHO III Anaplastic ependymoma, WHO III 6.6 9 10-5
Recurrent pilocytic astrocytoma, WHO I Anaplastic ependymoma, WHO III 0.0024
Ependymoma, WHO II Astrocytoma, WHO II \1 9 10-5
SEGA, WHO I Astrocytoma, WHO II \1 9 10-5
Glioblastoma, WHO IV Ependymoma, WHO II \1 9 10-5
Pilocytic astrocytoma, WHO I Ependymoma, WHO II \1 9 10-5
Recurrent anaplastic astrocytoma, WHO III Ependymoma, WHO II \1 9 10-5
Recurrent astrocytoma, WHO II Ependymoma, WHO II 0.017
Recurrent pilocytic astrocytoma, WHO I Ependymoma, WHO II 7.2 9 10-5
Recurrent astrocytoma, WHO II Glioblastoma, WHO IV 0.0039
Recurrent ependymoma, WHO II Glioblastoma, WHO IV 5.1 9 10-5
SEGA, WHO I Glioblastoma, WHO IV \1 9 10-5
Recurrent astrocytoma, WHO II Pilocytic astrocytoma, WHO I \1 9 10-5
Recurrent ependymoma, WHO II Pilocytic astrocytoma, WHO I \1 9 10-5
SEGA, WHO I Pilocytic astrocytoma, WHO I \1 9 10-5
Recurrent ependymoma, WHO II Pilocytic astrocytoma, WHO I \1 9 10-5
SEGA, WHO I Recurrent anaplastic astrocytoma, WHO III 2.1 9 10-3
Recurrent pilocytic astrocytoma, WHO I Recurrent ependymoma, WHO II 0.031
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OLIG2 was performed in Tris buffer pH 8 at 90 for
60 min, and for Ki-67 performed in Tris buffer pH 8 at 90
for 30 min. All immunohistochemistry was performed on
the Ventana Medical Systems Benchmark XT using the
Ultraview (multimer) detection system. Negative staining
in endothelial cells was used as an internal negative con-
trol. Dual labeling for OLIG2 and Ki-67 was also per-
formed using the Ventana Medical Systems Benchmark XT
using Ultraview DAB (OLIG2) and RED (Ki-67)
chromogens.
Immunohistochemistry scoring
Patient ‘‘cases’’ were defined as all surgical biopsies/
resection tissue from a single surgical procedure and
included all tissue submitted to pathology. All cases were
reviewed and scored independently by two of the authors
(Drs. Vandenberg and Otero) for the OLIG2 immunoper-
oxidase stain. This antibody has been validated in other
studies and is immunoreactive in various tumor cells of
adult gliomas [23]. A corresponding H&E stained section
was also available to confirm the OLIG2 immunoreactivity
in tumor cell nuclei. Microvascular cells were internal
negative controls. Cases were scored for OLIG2 tumor
expression as follows: score 0 corresponded to no OLIG2
staining in the tumor cells; score 1 corresponded to OLIG2
staining in 1–25% of tumor cells; score 2 corresponded to
OLIG2 staining in 26–75% of tumor cells; score 3 corre-
sponded to OLIG2 staining in more than 75% of tumor
cells. The scoring was done independently by two of the
authors (Drs. Vandenberg and Otero) with similar results.
Images shown in Figs. 2, 3, 4 and 5 demonstrate repre-
sentative fields of selected cases. For cases with multiple
sections/case, the score of all of the sections were averaged
into a final ‘‘case score.’’ The results from all of the cases
of a particular tumor type (cases were categorized by
diagnosis and tumor site in Tables 1, 2 and 3) are derived
from means of the score for each case (this includes
averages from cases with multiple sections/case as well as
the score from cases with one section/case).
Fig. 1 Distribution of primary
brain tumor per anatomical site
in this patient cohort. The
distribution of brain tumors per
anatomical site is illustrated in
pie charts. Below the pie chart is
its anatomical site; to the right
of the pie chart is the total
number of cases (n) in that site.
The largest proportions of
tumors in the respective sites
were: occipital lobe -[
anaplastic astrocytoma (2 of 2
total cases); frontal/temporal/
parietal cortex -[astrocytoma
WHO II (6 of 21 total cases);
posterior fossa -[pilocytic
astrocytoma (18 of 24 total
cases); deep gray matter -
[pilocytic astrocytoma (5 of 14
total cases); brainstem -
[astrocytoma, WHO II (4 of 11
cases); ventricle/periventricular
-[anaplastic astrocytoma WHO
III, SEGA WHO I,
ependymoma (each were 2 of 8
total cases); spinal cord -
[pilocytic astrocytoma,
ependymoma WHO II,
myxopapillary ependymoma
(each were 2 of 8 total cases);
optic nerve -[anaplastic
astrocytoma WHO III (1 of 1
total case); suprasellar -
[pilocytic astrocytoma (1 of 1
total case)
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Dual-label OLIG2-Ki67 immunohistochemistry
Selected cases that were dual-immunolabeled for OLIG2
and MIB-1 included pilocytic astrocytoma, infiltrating
astrocytoma WHO grade II, anaplastic astrocytoma WHO
grade III, and one glioblastoma multiforme. Staining was
performed with hematoxylin counterstain to verify the
labeled tumor cells and to exclude labeled inflammatory
and/or vascular nuclei and without hematoxylin counter-
stain to optimize the quantitative detection of dual-labeled
cells. A replicate slide without hematoxylin counterstain
was used for all quantifications as this facilitated detection
of dual labeled cells. Quantification was performed using
the technique for Ki-67 labeling indexes in gliomas used by
Colman and colleagues [24]. Briefly, digital pictures of the
tissue samples were taken and cell counts were determined
using the open source ImageJ cell counter software (http://
rsbweb.nih.gov/ij/). Three of five infiltrating astrocytoma
WHO grade II and one in six anaplastic astrocytoma WHO
grade III had fewer than 1000 tumor cell nuclei per slide.
All other cases had over 1000 cell nuclei analyzed. Nuclei
of Ki67?/OLIG2-cells were bright pink-red color whereas
Ki67?/OLIG2? were dark red-brown in this dual color
reaction.
Genetic analysis of BRAF in pediatric gliomas
Select cases had been evaluated for BRAF alterations,
including BRAFV600E missense mutations and KIAA1549-
BRAF fusion transcripts. BRAF analysis of these cases was
reported previously by Schiffmen et al. [22]. To evaluate
statistical correlations, Fisher Exact Test was performed
using R v2.11.1, an open source statistical framework run on
MAC OS Terminal (http://cran.r-project.org/).
Fig. 2 OLIG2
Immunoreactivity in pilocytic
astrocytomas (WHO Grade I)
and diffuse-type astrocytomas
(WHO Grade II–III).
Representative images of the
following tumor types illustrate
the most common expression
patterns. Pilocytic astrocytoma:
(a) Hematoxylin and eosin.
(b) OLIG
immunohistochemistry.
Diffuse-type astrocytoma,
WHO Grade II:
(c) Hematoxylin and eosin.
(d) OLIG
immunohistochemistry.
Diffuse-type astrocytoma,
WHO Grade III:
(e) Hematoxylin and eosin.
(f) OLIG
immunohistochemistry. a and
b are split with low
magnification images on the left
and high magnification images
on the right. Most pilocytic
astrocytomas showed near
universal, diffuse OLIG2
expression
J Neurooncol (2011) 104:423–438 427
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In silico analysis of ependymoma and juvenile pilocytic
astrocytoma Affymetrix microarray data
The ependymoma microarray dataset performed by John-
son et al. [25], the juvenile pilocytic astrocytoma micro-
array dataset performed by Sharma et al. [26], and the
pediatric high grade glioma dataset performed by Paugh
et al. [11] were downloaded from the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/). The epen-
dymoma and pilocytic astrocytoma datasets had been per-
formed using the Affymetrix HG-U133 plus 2 GeneChip
mircroarray using similar techniques. Ependymoma GEO
accession number is GSE21687 and the pilocytic astrocy-
toma GEO accession number is GSE5675. The high grade
glioma dataset GEO accession number is GSE19578.
Evaluation of the pediatric high grade glioma dataset per-
formed by Paugh et al. [11] was not directly compared to
the pilocytic astrocytoma and ependymoma data as the test
design was performed in a distinct fashion. This high grade
dataset is composed of single microarrays from multiple
patients. In addition, quality control analysis showed sig-
nificant differences in average probe pm intensities as well
as occasional arrays with RNA degradation that was sig-
nificantly different from the ependymoma and pilocytic
astrocytoma datasets. The ependymoma and pilocytic
astrocytoma datasets were composed of triplicates, resulting
in three .cel files in both the ependymoma and pilocytic
astrocytoma arrays. The .cel files were read into the R
v2.11.1 using Bioconductor’s affy library package (http://
www.bioconductor.org/), an open source R library package
routinely used for the analysis of microarray data [27]. An
Affybatch object was instantiated containing all files with the
probe level data (three .cel files from the ependymoma
dataset and three .cel from the pilocytic astrocytoma data-
set). In the case of the high grade glioma dataset, .cel files
corresponding to glioblastoma patients were used
Fig. 3 Patterns of OLIG2
Immunoreactivity in Pediatric
Glioblastoma, WHO grade IV.
Three examples of
Glioblastoma (WHO grade IV)
are illustrated to demonstrate
distinct patterns of OLIG2
expression. a, c, e show H&E
stained sections and c, d, and
f illustrate OLIG2
immunohistochemistry. The
first case (17 year old male with
spinal cord GBM, a, and b,
demonstrates widespread
OLIG2 expression in tumor
cells. Another pattern noted is
illustrated in c and d (8 year old
female with a right thalamic
GBM). Note the biphasic
pattern of OLIG2 expression in
this tumor. The more primitive
cellular OLIG2? population
was GFAP immunoreactive
(d inset, dual label OLIG2
brown-GFAP red). e and
f (9 year old male with temporal
lobe GBM) shows the typical
perineuronal and perivascular
invasive pattern at the edge of a
GBM. Note that the OLIG2
expressing cells at the
infiltrative edge of the tumor do
not have a specific distribution
pattern
428 J Neurooncol (2011) 104:423–438
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to instantiate an Affybatch object composed of 28 .cel files.
Background correction and normalization was performed
using Bioconductor’s expresso function (settings used: nor-
malize.method = ‘‘qspline’’, bgcorrect.method = ‘‘rma’’
[28–30], pmcorrect.method = ‘‘pmonly’’, summary.method
= ‘‘liwong’’ [31]). The expression measures were derived by
use of robust multiarray average (RMA). Expression mea-
sures were then written to a .txt or .csv file for further anal-
ysis. To determine differential gene expression between the
ependymoma and pilocytic astrocytoma microarrays, RMA
correction of the Affybatch object containing all .cel files was
performed and evaluated with the lmFIt and topTable func-
tions of Bioconductor’s limma package [32]. Quality control
analysis of the microarray data was performed using Bio-
conductor’s QCReport package (http://bioconductor.org/
packages/2.6/bioc/html/affyQCReport.html); quality con-
trol data for the two array studies derived from QCReport is
shown in Supplementary Fig. 1.
Conversion of affymetrix gene ID to gene names was
done with the David Gene ID conversion tool (http://
david.abcc.ncifcrf.gov/) [33, 34]. Table 6 lists known
genes with the most significant differential expression as
determined by the lmFit function of Bioconductor’s limma
package. Log fold change (logFC) and statistical analysis
of differential gene expression in Table 6 was performed
by the lmFit function. Table 7 lists the expresso derived
RMA expression measures of the ependymoma and pilo-
cytic astrocytoma arrays of genes known to be expressed in
stem cell, astrocytic, oligodendroglial, and ependymal cell
lineage of non-neoplastic brain. RMA expression mea-
sures of E-box containing genes that showed differential
expression in OLIG2 null versus wild-type neurospheres as
described by Ligon et al. [9] were evaluated using similar
techniques. Paired, two-tailed student’s t-test was used to
calculate P-values of the expression measures listed in
Tables 6 and 7.
Fig. 4 OLIG2
Immunohistochemistry in
pediatric ependymomas. H&E
stained sections for pediatric
ependymomas are illustrated on
the left panels with the
corresponding OLIG2
immunohistochemistry on the
right. The majority of
ependymomas showed no
staining for OLIG2 as shown in
b. One recurrent ependymoma
(8 year old male with a
posterior fossa mass) showed
focal OLIG2 positive tumor
cells (d). Included in the study
cohort was one patient with
myxopapillary ependymoma
that shows intense and diffuse
OLIG2 staining (f)
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Results
Distribution of pediatric brain tumor cases
As shown in Table 1, the most common brain tumor in the
patient cohort was the pilocytic astrocytoma, accounting
for 36% of the tumors studied. However, infiltrating
astrocytomas (i.e., all astrocytoma WHO II, III, and IV) as
a group exceeded the number of pilocytic astrocytoma
cases, accounting for 42% of the cases studied. Astrocy-
tomas are therefore slightly over represented in this cohort
compared to that reported in the CBTRUS, in which
pilocytic astrocytomas (WHO grade I) comprise 14–20%
of tumors and infiltrating astrocytomas range from 11–15%
of tumors [2].
Anatomical site of the tumors is listed in Table 3, and
the distributions of tumor type per anatomical site is
illustrated in Fig. 1. The most common tumor site was the
posterior fossa (26.7%), followed by the cerebral hemi-
spheres (in toto, 25.6%). As the specific proportion of
cortical based and cerebellar based brain tumors are
slightly increased relative to the CBTRUS population (18
and 16%, respectively), these tumor sites are overrepre-
sented in this cohort. Infiltrating astrocytomas (WHO
Grades II–IV) accounted for the majority of the tumors
arising in the cerebral hemispheres, while the majority of
posterior fossa tumors were pilocytic astrocytomas (Fig. 1).
Distribution of OLIG2 expression in pediatric tumors
All astrocytic tumors, including all pilocytic astrocytomas
(WHO Grade I) and the diffuse-type astrocytomas (WHO
Grades II–IV) showed diffuse OLIG2 expression (Table 1).
The glioblastomas and the pilocytic astrocytomas had the
highest mean OLIG2 score, followed by the diffuse-type
infiltrating astrocytomas WHO grade II–III. The primary
ependymomas (including anaplastic ependymoma, WHO
grade III) and two subependymal giant cell astrocytoma
were noteworthy for the absence of OLIG2? cells. Eval-
uation of adult ependymomas also showed a near absence
Fig. 5 OLIG2/Ki-67 dual
immunohistochemistry of
pediatric gliomas. Select cases
of pediatric gliomas were dual
immunolabeled for OLIG2
(DAB chromogen) and Ki-67
(RED chromogen). a Pilocytic
astrocytoma, WHO Grade I;
(b) Diffuse-type astrocytoma,
WHO grade II; (c) Anaplastic
astrocytoma, WHO grade III;
(d) Glioblastoma, WHO grade
IV. High magnification views of
dual labeled anaplastic
astrocytoma (e) and
glioblastoma WHO IV (f) are
illustrated to highlight the
differences between OLIG2?/
Ki67? cells and OLIG2-/
Ki67? cells. Double arrows in
e and f are OLIG2-/Ki67? cells
and large arrowheads are
OLIG2?/Ki67? cells. The
majority of Ki67 positive cells
are also OLIG2 positive
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of OLIG2? tumor cells (i.e., non-recurrent adult ependy-
moma WHO II and non-recurrent pediatric ependymoma
WHO II were OLIG2 score = 0). The recurrent anaplastic
astrocytomas (WHO grade III) and the recurrent cellular
ependymomas tended to have a higher number of OLIG2?
cells in comparison to the corresponding primary tumors
whereas the recurrent lower grade astrocytic tumors (WHO
grade I and II) had much lower numbers of OLIG2? cells.
Analysis of variance (ANOVA) was performed to test the
significant differences between OLIG2 expressions
amongst the tumor types. The P-values of statistically
significant tumor comparisons derived from intergroup
comparison (performed by ANOVA/Tukey HSD test) are
listed in Table 2. In summary, OLIG2 expression in
SEGA and ependymomas were significantly lower than the
astrocytic neoplasms.
Figure 2 shows representative fields of the astrocytic
tumors: pilocytic astrocytoma, infiltrating astrocytoma
WHO grade II–III. Many of the pilocytic astrocytoma cases
showed near universal, diffuse OLIG2 expression, as
illustrated in Fig. 2b, left panel. Glioblastoma, as a group
showed intense OLIG2 expression, but the distribution
patterns of the immunoreactive cells varied. The most
common pattern was a relatively diffuse expression in
single cells or small cell clusters as shown in Fig. 3b. One
glioblastoma arising in the thalamus, illustrated in Fig. 3d,
demonstrated a biphasic pattern of OLIG2 expression with
majority of the OLIG2 immunoreactive nuclei in the more
poorly differentiated cells that were distributed in highly
cellular zones while the more differentiated astrocytic
phenotypes were OLIG2 negative. These poorly differen-
tiated, OLIG2? cells were also immunoreactive for GFAP
(Fig. 3d, inset). When an infiltrating edge of the glioblas-
tomas was available for analysis, OLIG2 positive tumor
cells were present in the populations of tumor cells infil-
trating the surrounding brain; however, in contrast to the
overall tendency for localization of the tumor cells in
perineuronal and perivascular zones, OLIG2? cells did not
show a preferential perineuronal satelitosis or perivascular
structuring (Figs. 2e, f).
A total of 16 pediatric ependymomas were tested for
OLIG2 expression. Representative photographs of OLIG2
stained ependymomas are shown in Fig. 3. The majority of
cases (13 of 16) showed no significant OLIG2 expression
(score = 0). One case of myxopapillary ependymoma
showed a diffuse, strong expression of OLIG2. A second
case of myxopapillary ependymoma showed no OLIG2
expression. Discrete zones of OLIG2? cells were present
in one case of recurrent cellular ependymoma in an 8-year
old boy (see Fig. 3d) and in one case of a 17-year old boy
with a fourth ventricular anaplastic ependymoma, WHO III
(data not shown). The OLIG2 staining pattern in the
recurrent pediatric ependymoma is more typical of that
described in adult ependymomas [23]. Taken together,
18.8% of pediatric ependymoma cases showed at least
some OLIG2 expression, a result similar to that reported
by other investigators [35–37]. Comparison of OLIG2
expression in adult ependymomas showed similar results to
the pediatric ependymomas (mean OLIG2 score = 0). No
adult myxopapillary ependymomas (0 of 3 total cases)
showed significant OLIG2 expression.
Tumor type and anatomic site affecting OLIG2
expression
Although the level of OLIG2 expression appeared to vary
according to tumor site (Table 3), this trend usually
resulted from the disparity of specific tumor types that were
associated with particular anatomic zones. However, the
anaplastic astrocytomas that arose in the occipital lobes had
low OLIG2 expression compared to other sites, and
regardless of tumor type, tumors arising in the deep
supratentorial midline structures (suprasellar, optic nerve,
thalamus) typically had high levels of OLIG2 expression.
The anatomical site that showed the highest OLIG2
expression was the deep cerebral gray matter (average
OLIG2 score of 2.7). The anatomical sites with the lowest
OLIG2 expression were intraventricular tumors (average
OLIG2 score = 0.66). Intraventricular tumors were chiefly
composed of low OLIG2 expressing tumors such as SEGA
and ependymoma. Tumors arising in the frontal/temporal/
parietal cerebral cortex show a large variation in OLIG2
expression (standard deviation of OLIG2 score = 1.2).
Table 3 OLIG2 expression in primary brain tumor anatomical site
Tumor site n Ave. age M/F Mean
OLIG2
score
SD
Optic nerve 1 3 1M/0F 3 N/A
Suprasellar zone 1 3 0M/1F 3 N/A
Deep cerebral gray matter 14 6.1 8M/6F 2.7 0.6
Posterior fossa/cerebellum 24 8.3 11M/13F 2.4 1
Brainstem 11 7.4 6M/5F 2.5 0.82
Spinal cord 8 13.1 4M/4F 2 1.4
Frontal-temporal-parietal
lobes
21 9.9 13M/8F 1.8 1.2
Occipital lobes 2 6 2M/0F 1 0
Ventricular system 8 9.9 4M/4F 0.6 1.1
Primary brain tumors were analyzed for OLIG2 expression by
immunohistochemistry. The results of the anatomical sites are shown
here. Tumors arising in the ventricular system showed markedly
decreased OLIG2 expression
n total number of cases, y years, M/F number male patients/number
female patients, ST dev standard deviation, Occipital all tumors
arising in the occipital lobe, Subcortical Grey matter all tumors
arising in thalamus, hypothalamus, and basal ganglia nuclei
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Most astrocytic neoplasms arising in frontal/temporal/par-
ietal cerebral cortex showed diffuse levels of OLIG2
expression; however, three cases of anaplastic ependy-
moma, WHO III showed low OLIG2 expression (OLIG2
score = 0), which accounts for the large variability (stan-
dard deviation = 1.2). Statistical analysis by ANOVA and
Tukey HSD test demonstrates that only ventricle-brain-
stem, ventricle-deep deep gray matter, and ventricle-pos-
terior fossa comparisons were statistically significant
(P = 0.005, 0.0009, 0.002, respectively). OLIG2 expres-
sion differences between all other sites were not statisti-
cally significant (in all instances, P [ 0.05).
Cellular proliferation and OLIG2? expression
OLIG2 regulates replication competence in a genetically
relevant murine model [9]. To test if proliferating cells
were OLIG2 positive, the proportion of Ki67? cells that
were also OLIG2? were determined in selected cases of
pilocytic astrocytoma, infiltrating astrocytoma WHO grade
II, anaplastic astrocytoma WHO grade III, glioblastoma
WHO grade IV, and ependymoma WHO grade II. Dual
labeling immunohistochemistry for OLIG2 and Ki-67 was
performed without a hematoxylin counterstain. Hence, to
obtain a surrogate Ki67 labeling index in the cases exam-
ined, the proportion of OLIG2? cells that are also Ki67?
was determined. Results for astrocytoma are listed in
Table 4, and examples of dual labeling are shown in Fig. 5.
Glioblastoma had the highest percentage of OLIG2
expressing cells that were also Ki-67 positive (i.e., mean
(number of OLIG2? Ki67? cells)/total Ki67?
cells = 16.3%) and also the highest subpopulation of
OLIG2- cells within the fraction of proliferating cells (i.e.,
mean (number of OLIG2-Ki67? cells)/total Ki67?
cells = 15.5%). Most of the proliferating (Ki-67 positive)
cells in the diffuse-type astrocytomas (WHO grade II-III)
Table 4 OLIG2 and Ki67 dual quantifications in pediatric human gliomas
Case number Diagnosis Percentage of OLIG2? cells
that are also Ki67?
Percentage of Ki67? cells that
are also OLIG2 positive
1 Pilocytic astrocytoma, WHO grade I 1.6 100
2 Pilocytic astrocytoma, WHO grade I 0 *
3 Pilocytic astrocytoma, WHO grade I 0 *
4 Pilocytic astrocytoma, WHO grade I 0.6 88.9
5 Pilocytic astrocytoma, WHO grade I 0.1 100
6 Pilocytic astrocytoma, WHO grade I 0 *
7 Pilocytic astrocytoma, WHO grade I 5 80.3
8 Pilocytic astrocytoma, WHO grade I 0 *
9 Pilocytic astrocytoma, WHO grade I 0.5 54.5
Mean of pilocytic astrocytoma 0.9 (SEM = 0.5) 85.0 (SEM = 6.2)
1 Astrocytoma, WHO grade II 0.1 100
2 Astrocytoma, WHO grade II 0.5 100
3 Astrocytoma, WHO grade II 1.7 100
4 Astrocytoma, WHO grade II 2 71.4
5 Astrocytoma, WHO grade II 0.9 100
Mean of astrocytoma, grade II 1.0 (SEM = 0.3) 94.3 (SEM = 5.7)
1 Anaplastic astro, WHO grade III 0.2 100
2 Anaplastic astro, WHO grade III 12.4 92.9
3 Anaplastic astro, WHO grade III 2.4 86.2
4 Anaplastic astro, WHO grade III 1 94.1
Mean anaplastic astrocytoma 4.9 (SEM = 2.8) 93.3 (SEM = 2.8)
1 Glioblastoma Multiforme WHO grade IV 9.2 80.4
2 Glioblastoma Multiforme WHO grade IV 23.6 88.7
Mean of glioblastoma 16.3 (SEM = 7.2) 84.5 (SEM = 4.1)
Dual labeling indexes were determined for select tumors (see methods). The percentage of OLIG2-positive cells that are also Ki67-positive cells
is calculated by dividing the number of double positive cells by the total number of OLIG2-positive cells, or %[(Ki67? OLIG2?)/OLIG2?].
The percentage of Ki67-positive cells that are also OLIG2 positive cells is calculated by taking the number of double positive cells divided by the
total number of Ki67 positive cells, or %[(Ki67?/OLIG2?)/Ki67?]. Statistical analysis by ANOVA discloses no statistical significance between
the data sets presented. Cases with * showed no Ki67? cells in the tissue section
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were also OLIG2? (i.e., (number of OLIG2? Ki67?
cells)/total Ki67? cells = 92–94%). However, the mean
proportion of OLIG2? cells that were also Ki67? (i.e.,
(number of OLIG2? Ki67? cells)/total OLIG2? cells)
varied from 1.0–16.3%. The mean proportion of OLIG2?
cells that were also Ki67? showed a trend to being asso-
ciated with increasing tumor grade. As expected, statistical
analysis by ANOVA/TukeyHSD test showed the mean
proportion of OLIG2? cells that were also Ki67? in
glioblastoma multiforme WHO IV to be significantly dif-
ferent from pilocytic astrocytoma, astrocytoma WHO II,
and anaplastic astrocytoma WHO III (P = 0.007, 0.0008,
0.0004, respectively). This finding is in concurrence with
data showing a higher Ki67 labeling index in glioblastoma
relative to lower grade astrocytomas.
Even though the overall rate of cell proliferation in
pilocytic astrocytomas was very low, about 85% of the
proliferating cells were also OLIG2? , which represented
only about 1.6 percent of all cells expressing OLIG2. All
the ependymoma cases that were OLIG2- showed scat-
tered Ki67 positive nuclei throughout the tissue sections
(data not shown). The average percentage of Ki67 ? cells
that were also OLIG2 ? were 84.6% (st. err. = 6.2) for
pilocytic astrocytoma, 94.3% (st. err. = 5.7) for grade II
astrocytoma, and 92.3% (st. err. = 2.4) for anaplastic
astrocytoma WHO grade III. Statistical analysis by
ANOVA did not demonstrate any significant difference
between astrocytoma groups but did show difference
between astrocytoma-ependymoma groups.
BRAF mutation shows no correlation with OLIG2
expressing tumors
Evaluation of BRAF mutation status in a subset of pediatric
gliomas is presented in Table 5. To test an association
between OLIG2 score and BRAF mutation, contingency
tables were created and analyzed by the Fisher Exact Test.
Groups were separated into BRAF mutated (which included
BRAFV600E missense mutations and KIAA1549-BRAF
fusion transcripts) and BRAF non-mutated. The OLIG2
contingency table separated the patients listed in Table 5
into patients with an OLIG2 score of 3 (BRAF mutated
n = 6, BRAF non-mutated n = 4), and an OLIG2 score\3
(BRAF mutated n = 0, BRAF non-mutated n = 2). No
statistically significant association between OLIG2 expres-
sion and BRAF mutation was determined (P = 0.45).
Tumor type contingency tables were constructed for pilo-
cytic astrocytoma (BRAF mutated n = 4, BRAF non-
mutated n = 0), astrocytoma WHO II ((BRAF mutated
n = 1, BRAF non-mutated n = 3), anaplastic astrocytoma
WHO III (BRAF mutated n = 1, BRAF non-mutated
n = 2), and glioblastoma (BRAF mutated n = 0, BRAF
non-mutated n = 1). No statistically significant correla-
tion was identified between the presence of a BRAF
mutation and tumor diagnosis (P = 0.11). However, a
statistically significant association between the presence of
KIAA1549-BRAF fusion transcripts in pilocytic astrocy-
toma and its absence in the other tumor groups was noted
(P = 0.006).
Table 5 OLIG2 expression and BRAF analysis in pediatric gliomas
Case # Site Diagnosis OLIG2 score BRAF Other
4035 Spinal cord Pilocytic astrocytoma (WHO I) 3 K16-B9 None
2974 Cerebellum Pilocytic astrocytoma (WHO I) 3 K16-B11 None
2085 Cerebellum Pilocytic astrocytoma (WHO I) 3 K16-B9 None
4035 Spinal cord Pilocytic astrocytoma (WHO I) 3 K16-B9 None
2652 Deep grey Astrocytoma (WHO II) 1 None None
2995 FTP Astrocytoma (WHO II) 3 None None
4282 Cerebellum Astrocytoma (WHO II) 3 K16-B9 None
4825 FTP Astrocytoma (WHO II) 3 None None
7269 Deep grey Astrocytoma, anaplastic (WHO III) 3 None None
1734 FTP Astrocytoma, anaplastic (WHO III) 3 V600E NONE
1762 IV Astrocytoma, anaplastic (WHO III) 1 None TP53, 273:R[H
7124 FTP Glioblastoma multiforme 3 None TP53, 172; V[F, PIK3C2B/MDM4 (A),
MYC/PVT1(A)
Surgical site, OLIG2 expression, and results from BRAF analysis in pediatric gliomas are presented. BRAF and KIAA1549 fusions are depicted
by the points of exon fusion (e.g., K16-B9 is KIAA1549 exon 16 fused with BRAF exon 9). No statistical difference was noted in OLIG2 score,
surgical site, or diagnosis with regards to BRAF mutation. A statistically significant association between IAA-1549-BRAF fusion and the
diagnosis of pilocytic astrocytoma was noted
J Neurooncol (2011) 104:423–438 433
123
In silico analysis of ependymoma and astrocytoma
tissue microarray datasets
Pilocytic astrocytoma and ependymoma transcriptional
expression datasets obtained from previously published
Affymetrix expression microarrays were evaluated (see
methods). Quality control assessment of the ependymoma
and pilocytic astrocytoma datasets demonstrated similar
average probe signal intensities and high intergroup cor-
relation (Supplementary Fig. 1). In each group, one of
three arrays showed high RNA degradation. Significant
differential expression was noted in 1402 of 53272 genes
(significance threshold was set to P \ 0.05 by t-test). The
genes that were most significantly differentially expressed
in the two datasets are listed in Table 6. The P value
listed is an adjusted P value derived after Benferroni
correction of the limFit/TopTable P-value. Of interest,
SH2 showed significant differential expression with _s_at
probes. The _s_at is predicted to bind to more than one
transcript of the same gene family, suggesting that gene
family members are differentially expressed in these two
tumors.
Transcriptional comparison of OLIG2 genetically null
versus wild-type neural stem cells in mice demonstrated
differential expression in multiple E-box containing genes
[9]. This list of the differentially expressed genes reported
by Ligon et al. [9] was used to test for differential
expression between the pilocytic astrocytoma and epen-
dymoma microarray data. No statistically significant dif-
ferential expression of these E-box containing genes was
noted when comparing pilocytic astrocytoma and ependy-
moma array data (in all instances, P [ 0.05 by t-test).
Table 7 lists neural cell lineage associated genes for
neural stem cells, astrocytes, oligodendrocytes, and epen-
dymal cells. SOX2 and Aquaporin 4 showed significant
increased expression in ependymoma relative to pilocytic
astrocytoma. Of note, the _s_at probe for Aquaporin 4
showed no statistically significant difference between the
ependymoma and pilocytic astrocytoma datasets (P =
0.17), whereas the _at showed significant difference
(P = 0.005); this suggests that pilocytic astrocytomas may
express other genes of a similar family, but do not express
the Aquaporin 4 transcript. Relative to ependymomas, pil-
ocytic astrocytomas showed significantly increased
expression of nestin, OLIG1, OLIG2, and Oligodendrocyte
Myelin Glycoprotein (OMG). Of note, PLP1 showed ele-
vated RMA expression measures in pilocytic astrocytoma
relative to ependymoma, but the P value was slightly above
the threshold for significance set for this study (P = 0.06).
Increased expression of Rootletin, a structural protein
present in the cilia of ependymal cells [38–40], was sig-
nificantly higher in ependymoma relative to pilocytic
astrocytoma. In contrast to pilocytic astrocytoma, evalua-
tion of the pediatric glioblastoma expression dataset [11]
showed minimal expression of OMG (mean expression
measure = 416.2(81.3)).1 However, OLIG2, OLIG1, and
GFAP were highly expressed in pediatric glioblastoma
(mean expression measures 1085.9 (117.1), 2609.4 (426.5),
5499.8 (731), respectively) (see footnote 1).
Discussion
Differential OLIG2 expression in astrocytoma
and ependymoma
The transcription factor OLIG2 is expressed in neural
progenitor cells and controls replication competence in
both neural stem cells and malignant glioma [9]. In addi-
tion, OLIG2 expression in a human glioblastoma cell line
appeared to down-regulate in vitro cellular motility via
RhoA activation [41], suggesting that OLIG2 may regulate
various biologic functions in neoplastic glia. Although a
majority of the Ki67 immunoreactive cells in pilocy-
tic astrocytomas also expressed OLIG2, most OLIG2
expressing cells were not labeled with Ki67, since pilocytic
astrocytomas, as a low grade glioma, typically have a low
fraction of proliferating cells. In addition, these tumors
have very limited capacity to invade brain parenchyma and
tend to uniquely exhibit a circumscribed growth pattern,
Table 6 Top differentially expressed genes in ependymoma and
pilocytic astrocytoma
Gene symbol Ensembl # logFC p Probe type
CAM 2 ENSG00000175161 4.90 0.04 _at
FGF12 ENSG00000114279 4.35 0.04 _at
BAI-3 ENSG00000135298 4.18 0.03 _at
SH2 ENSG00000145147 -3.83 0.009 _s_at
Stonin2 ENSG00000140022 -4.24 0.02 _at
RMST n/a -6.54 0.02 _at
The most significantly differentially expressed genes between epen-
dymoma and pilocytic astrocytoma as determined by microarray
analysis are listed (see ‘‘Materials and Methods’’). Log fold change
(logFC) that is positive denotes genes that are upregulated in pilocytic
astrocytoma relative to ependymoma; logFC that is negative denotes
genes that were upregulated in ependymoma relative to pilocytic
astrocytoma. Affymetrix _at probe types hybridize with one specific
transcript whereas _s_at probe types are predicted to hybridize with
multiple transcripts of the same gene family. No ensembl id is present
for RMST, entrez gene id is 196475
RMST rhabdomyosarcoma transcript (non-protein encoding), FGF12
fibroblast growth factor 12, SH2 slit homolog 2 (Drosophila)
P adjusted P value from lmFit test using Benferroni correction
1 Number in parenthesis denotes standard error of the mean of RMA
derived expression measures from all pediatric glioblastoma patients.
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while exhibiting variable motility in the leptomeninges and
along white matter tracts. The OLIG2 expressing cells in
pilocytic astrocytomas may be a manifestation that these
unique astrocytomas arise from certain populations of
radial glia or early progenitor cells in common with oli-
godendroglial lineages [42]. Analyses of both sporadic and
NF1-associated pilocytic astrocytomas indicate cell-line-
age specific genetic signatures that correspond to regional
progenitor cell populations [43]. Comparative analyses of
gene expression in sporadic pilocytic astrocytomas dem-
onstrated expression of SOX10, PEN5, PLP, PMP-22,
MBP, and oligodendroglial myelin glycoprotein, suggest-
ing that these tumors are uniquely delineated from non-
neoplastic white matter and other low grade gliomas, and
are more similar to fetal astrocytes and to oligodendroglial
lineages [44–46]. Consistent with presence of oligoden-
droglial progenitors, pilocytic astrocytomas, especially
optic nerve tumors, contain significant numbers of O4
immunoreactive cells, and the highest numbers of A2B5 ?
glial progenitor cells are present in pilocytic astrocytomas
of the posterior fossa. An expression analysis of 21 juvenile
pilocytic astrocytomas presented additional evidence for
the relationship of pilocytic astrocytomas to a population of
radial glia or early progenitors. Neurogenesis was one of
the major biological processes with detection of 18
deregulated genes with the upregulation of four neuro-
genesis-related genes in these tumors [47–51]. The marked
upregulation of stem cell and oligodendrocyte lineage
genes relative to ependymoma determined in the tran-
scriptional microarray data presented in this study is in
concordance with previously reported findings.
In all of the diffuse astrocytomas examined, the over-
whelming majority of Ki67 positive cells were also OLIG2
positive. This is consistent with OLIG2’s role in neural
stem cell and glioma cell replication. However, in several
examples there were distinct populations of cells that
Table 7 Differential expression of neural lineage genes
Gene name Genbank # Diff exp in
OLIG2 null (Y/N)
Mean ExpM-EP
(st. err.)
Mean ExpM-PA
(st. err.)
ExpM-EP/ExpM-PA
Stem cell associated
SOX2 NM_003106 N 380.23 (13.57) 150.19(34.43) 2.53
Nestin NM_006617.1 N 254.07 (67.15) 558.29 (96.20) 0.46
BMI1 NMJW5180 Y 957.30 (62.73) 497.97 (90.02) 1.92
Anax6 NM_001155 Y 272.54 (34.65) 486.29 (57.96) 0.56
GFAP NM_002055 Y 11562.63(160.55) 12983.618(561.08) 0.89
Vimentin NM_003380 Y 5977.26 (262 44) 6479.32 (2993.85) 0.92
Numb NM_001005743.1 Y 61.27 (14.7) 46.47 (7.4) 1.3
CCND1 NM_053056.2 N 157.1 (55.68) 165.18(62.7) 0.95
EGFR-1 NM_005228 N 37.9 (3.37) 36.99 (4.37) 1.02
Astrocyte associated
Aqp4 (probe 1) NM_001650.4 N 339 93 (33.06) 64.16(110.18) 5.3
Aqp4 (probe 2) NMJW1650.4 N 3694(1736.48) 310.78 (47.43) 11.89
FGF3 NM_000t42.4 N 11.46(1.24) 10.59(102.42) 11.46
S100b NM_006272.2 N 2362.04 (858.537) 1827.56(1.72) 1.29
Oligodendrocyte associated
OLIG1 NM_138983.2 Y 134.82 (14.65) 2271.04 (328) 0.06
OLIG2 NM_Q00533.3 Y 66.88(19.87) 663.45(18.77) 0.1
OMB NM_138983.2 Y 56.92 (12.4) 545.61 (453.16) 0.1
PDGFRa (probe 1) NM 006206.4 Y 384.35 (264.4) 34.50(133.47) 1.16
PDGFRa (probe 2) NM 006206.4 Y 41.2 (16.984 35.4 (3.73) 1.17
MBP (probe 1) NM_001025081.1 Y 50.87(16.49) 150.01 (9.60) 0.3
MBP (probe 2) NM_OO1025O81.l Y 90.57 (34.76) 1431.30 (1332.39) 0.06
PLPI NM_000533.3 Y 355(125.54) 1455.24 (770.10) 0.24
Genes known to be expressed in the neural stem cell, astrocytic, oligodendroglial, and ependymal lineage are listed. Mean RMA derived
expression measures for ependymoma (ExpM-EP) and pilocytic astrocytoma (ExpM-PA). Relative expression of these genes is shown in column
(ExpM-EP/ExpM-PA). P = probability calculated by paired two-tailed student’s t-test. Diff exp in OLIG null (Y/N) refers to genes that were
differentially expressed in OLIG2 null neurospheres compared to wild-type neurospheres as determined by Ligon et al. [9]; Y = differentially
expressed, N = not differentially expressed. Affymetrix _at probe types hybridize with one specific transcript whereas _s_at probe types are
predicted to hybridize with multiple transcripts of the same gene family
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differentially expressed OLIG2. In one case of glioblas-
toma (illustrated in Fig. 2, panel D), a subset of polygonal,
GFAP negative cells had lost their OLIG2 immunoreac-
tivity, raising the possibility that the OLIG2 positive and
negative fractions of tumor cells may have different bio-
logical potential and/or function as shown in rodent stu-
dents [9]. Overall, these data are very similar to OLIG2
data found in adult patients with diffuse astrocytoma [23].
Hence, despite the different molecular signatures and
aberrancies between pediatric and adult diffuse astrocy-
toma, this data suggests that OLIG2 expression in astro-
cytoma may be conserved between these two age groups.
In comparison to adult gliomas, we found that, with the
exception of one case of myxopapillary ependymoma,
primary pediatric ependymomas did not significantly
express OLIG2. This differential expression of OLIG2 is
consistent with the different molecular signatures of adult
and pediatric ependymomas [52] and the unique molecular
characteristics of pediatric myxopapillary ependymomas
[53]. In one case of a recurrent ependymoma, scant OLIG2
immunoreactive cells could be seen, a pattern that is more
similar to their adult counterparts [17, 23, 54, 55].
Utility of OLIG2 expression in histopathologic
diagnosis of pediatric brain cancers
Our experience with the OLIG2 antibody indicates that this
reagent is suitable for routine immunohistochemistry on
formalin-fixed, paraffin embedded specimens. We were
capable of detecting OLIG2 immunoreactivity in pathology
specimens archived for up to 15 years. OLIG2 immuno-
histochemistry would not be an appropriate marker for
distinguishing astrocytomas of different grades. Minimal or
the complete absence of nuclear OLIG2 staining in WHO
grade II and grade III ependymomas may suggest that in
cases where ependymoma and astrocytoma are within the
differential diagnosis, OLIG2 immunohistochemistry could
aide in distinguishing these two entities. However, the
presence of diffuse OLIG2 nuclear staining in one of three
myxopapillary ependymomas raises the concern that rare
ependymomas may show diffuse OLIG2 nuclear staining.
In summary, diffuse OLIG2 nuclear staining in a glial
tumor cannot exclude ependymoma from the differential
diagnosis.
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